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Background and Aims: The total serum IgE level is a marker of immunological activity in
allergic bronchopulmonary aspergillosis (ABPA), and a 35% decline beyond six weeks is tradi-
tionally taken as criteria for remission. The aim of this study was to evaluate the magnitude
and clinical significance of decline in serum IgE levels at six weeks in patients with ABPA.
Methods: All consecutive patients with ABPA presenting to the Chest Clinic were followed up
with clinical evaluation, total IgE levels and chest x-ray every six weeks for three months. We
analyzed the percentage decline in IgE levels and correlated it with clinical outcomes of
relapse and complete remission.
Results: Of the 242 asthmatics, 54 were diagnosed with ABPA (29 males, 25 females; mean age-
34 years). There was clinical and radiological improvement at six weeks in all patients
receiving glucocorticoid therapy. The IgE levels fell by a mean of 38.8%, and the decline
was significantly higher in patients with baseline IgE levels >2500 IU/mL than with levels
2500 IU/mL (44% vs. 26%). Twenty-two patients did not attain a 35% decline in IgE levels,72 2756825; fax: þ91 172 2748215.
m (R. Agarwal).
9 Elsevier Ltd. All rights reserved.
Significance of IgE decline in ABPA 205and this number was significantly higher in patients with IgE levels <2500 IU/mL. On multivar-
iate analysis, the decline in IgE levels at six weeks did not predict clinical outcomes.
Conclusions: A 35% decline in serum IgE levels at six weeks is not seen in all patients with ABPA,
and the decline is slower in patients with baseline IgE levels <2500 IU/mL. The quantum
decline in serum IgE levels does not predict clinical outcomes.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmo-
nary disorder caused by a complex hypersensitivity
response to antigens released by the fungus Aspergillus
fumigatus.1 The clinical entity was first described by Hinson
et al. in 1952,2 and the clinical and immunologic signifi-
cance of A. fumigatus in the sputum were reported by
Pepys and coworkers in 1959.3 The prevalence of ABPA in
bronchial asthma is fairly high and a recent meta-analysis
suggested the prevalence of ABPA in asthma clinics to be as
high as 13 percent.4 Diagnostic criteria for ABPA have been
laid and generally include the following eight major
criteria: (a) history of asthma; (b) transient or fixed
pulmonary infiltrates; (c) immediate cutaneous hyperre-
activity to A. fumigatus antigen; (d) absolute eosinophil
count >1000/mL; (e) serum precipitins against A. fumiga-
tus; (f) total IgE levels >1000 IU/mL; (g) central bronchi-
ectasis on high-resolution computed tomography (HRCT);
and, (h) raised A. fumigatus specific IgE or IgG levels.5
However, none of these are specific for ABPA,6e14 and there
is still no consensus on the number of criteria needed for
diagnosis, and patients in different stages of ABPA may not
fulfill all these criteria.1,6
Similarly, there is no established definition for remis-
sion of ABPA. The most widely followed criteria are clin-
ical and radiological improvement with at least 35 percent
decline in total serum IgE levels. However, this criterion
for remission is based on the results of a single retro-
spective study.15 This criterion has not been further
studied in detail. Moreover the clinical significance of
decline in serum IgE levels is not known especially with
regards to clinical outcome. There is a dramatic fall in the
total serum IgE levels with institution of glucocorticoids in
patients with ABPA with associated radiological and clin-
ical improvement.16 The total serum IgE level is a marker
of immunological activity in ABPA, and it is probable that
the changes in total serum IgE levels especially the
magnitude of fall be associated with clinical outcomes in
terms of relapse and ability to achieve complete
remission.
The disorder is highly prevalent in India. We have
previously reported our experience with screening stable
outpatients with bronchial asthma and acute severe
asthma for ABPA.17,18 We have also recently reported the
prognostic factors associated with clinical outcomes in
patients with ABPA.19 The aim of this manuscript was to
evaluate the magnitude of fall of total serum IgE levels
at six weeks, and the clinical significance of the
quantum decline in total serum IgE levels with regards to
relapse and propensity to maintain sustained clinical
remission.Patients and methods
The present study is a retrospective analysis of prospec-
tively collected data, and includes all consecutive treat-
ment-naive patients of ABPA diagnosed between July 2006
and June 2008. We have been prospectively screening all
consecutive patients with asthma presenting to the Chest
clinic of our institution with an aspergillus skin test.
Patients who were found to demonstrate immediate cuta-
neous hyperreactivity to aspergillus antigen were further
investigated. The patients were considered to have ABPA if
they met both the following criteria: elevated total IgE
levels (more than 1000 IU/mL) and elevated IgE levels
against A. fumigatus (more than 0.35 kU per liter); and,
two of the following criteria: presence of serum precipi-
tating antibodies against A. fumigatus, radiographic
pulmonary opacities (fixed/transient), absolute eosinophil
count more than 1000/mL and central bronchiectasis on
HRCT.17 Patients who had taken glucocorticoids for more
than three weeks in the preceding six months were
excluded from screening. None of the patients were
screened for cystic fibrosis. All patients were screened with
routine stool examination to exclude parasitic infestations.
The study was cleared by the Institute Ethics Committee,
and an informed consent was taken from all patients as per
protocol.
Aspergillus skin test was performed using A. fumigatus
antigen prepared in the Department of Medical Mycology.
It was read every 15 min for 1 h, and then after 6e8 h. The
reactions are classified as type I if wheal and erythema
developed within a minute, reached a maximum after
10e20 min and resolved within one to two hours; and, type
III reaction if any amount of subcutaneous edema was
present after 6 h. Levels of serum IgE (total) and IgE (for
A. fumigatus) were assayed with commercially available
kits using the quantitative enzyme-linked immunosorbent
assay (Demeditec diagnostics GmbH, Kiel, Germany) and
the fluorescent enzyme immunoassay (UniCap Systems;
Pharmacia Upjohn; Stockholm, Sweden). A. fumigatus
precipitins were detected by the Ouchterlony’s gel diffu-
sion techniques according to the method of Longbottom
and Pepys.10 Spirometry with bronchodilator reversibility
was performed using commercial spirometer (Morgan
RS-232 Spiro), and patients were categorized to have mild,
moderate and severe obstruction as per the standardized
practice in our laboratory.20 Bronchodilator reversibility
was considered to be significant if, after 200 mg of inhaled
salbutamol, the forced expiratory volume in the first
second (FEV1) and/or forced vital capacity (FVC) increased
by more than 12% and 200 mL.21 Absolute eosinophil count
was performed manually by counting the cells on the
peripheral smear. High-resolution CT of the thorax (IV
Table 1 Baseline characteristics of the 54 patients with
allergic bronchopulmonary aspergillosis.
Clinical characteristics Results
Clinical findings
Age in years 34.3 (30.6e38.0)
Male sex 29 (53.7; 40.6e66.3)
Duration of asthma in years 10.9 (8.0e13.9)
Hemoptysis 12 (22.2; 13.2e34.9)
Expectoration of brownish-black
mucus plugs
15 (27.8; 17.6e40.9)
Intake of anti-tuberculous therapy 18 (33.3; 22.2e46.6)
Spirometry
Normal 12 (22.2; 13.2e34.9)
Mild obstruction 14 (25.9; 16.1e38.9)
Moderate obstruction 21 (38.9; 27.0e52.2)
Severe obstruction 7 (12.9; 6.4e24.4)
Bronchodilator reversibility 24 (44.4; 32.0e57.6)
Immunological findings
Aspergillus skin test
206 R. Agarwal et al.contrast was not administered) was performed on a 16-row,
multiple detector, CT scanner (LightSpeed Plus; GE Medical
Systems; Slough, UK) with a 512 matrix size. The scans
(120 kV; 10 mA; window width, 1500 Hounsfield units [HU];
and window level, 600 HU) were obtained with a scan time
of three seconds in the supine position at full end-inspira-
tion from lung apex to base. The image acquisition was
contiguous and the images (1.25 mm at 10-mm intervals)
were reconstructed using the high-spatial-frequency algo-
rithm. Gross localization of individual bronchopulmonary
segments were identified by the anatomical division of the
appropriate lobar and segmental bronchus, and their rela-
tionship with the major and minor fissures.22,23 The radio-
logical abnormalities were categorized for the presence
and extent of bronchiectasis with the criteria described by
Reiff et al. used to classify bronchiectasis.24 Bronchiectasis
was classified as ‘central’ when confined to the medial half
of the lung, at a point midway between the hilum and the
chest wall.25 The presence of high-attenuation mucus was
considered if the mucus plugs were visually denser than the
normal skeletal muscle.26
The patients were treated with glucocorticoids with the
following regimen: prednisolone 0.75 mg/kg for six weeks,
0.5 mg/kg for six weeks; then tapered by 5 mg every six
weeks to continue for a total duration of at least six to
twelve months. No patient received itraconazole or any
other azole derivatives. The patients were followed up with
history and physical examination, chest radiograph and IgE
levels (total) every six weeks. A repeat CT scan was not
done unless a complication was suspected. Patients were
classified as having remission e if the IgE levels declined by
more than 35 percent and there was clearance of chest
radiographic lesions after three months of glucocorticoids,
relapse e doubling of the baseline IgE levels irrespective of
the patient’s symptoms or appearance of radiologic infil-
trates, complete remission e no ABPA exacerbations over
the next 3 months after stopping therapy, glucocorticoid-
dependent ABPA e patient required oral prednisolone for
recurrent relapses of ABPA and end-stage ABPA e extensive
bronchiectasis with either cor pulmonale and/or type 2
respiratory failure.8 For the purpose of this study, IgE levels
were noted at baseline and six weeks after glucocorticoid
therapy and percentage decline was calculated as: (base-
line IgE levels minus IgE levels after six weeks of gluco-
corticoid therapy) divided by baseline IgE levels.Type 1 54 (100; 93.4e100)
Type 3 38 (70.4; 57.2e80.9)
Absolute eosinophil count
per microliter
1145.8 (897.6e1393.9)
A. fumigatus precipitins No (%) 42 (77.8; 65.1e86.8)
IgE levels (total), IU/mL 7829.4 (5977.1e9681.7)
IgE levels (A. fumigatus), kUA/L 15.0 (9.41e20.59)
HRCT findings
Normal HRCT 10 (18.5; 10.4e30.8)
Extent of bronchiectasis
Lobes 2.7 (2.3e3.2)
Segments 6.8 (5.4e8.2)
High-attenuation mucus 12 (22.2; 13.2e34.9)
All the results are expressed as mean (95% confidence intervals)
and number (percentage with 95% confidence intervals) unless
otherwise stated.Statistical analysis
Statistical analysis was performed using the statistical
package SPSS for MS-Windows (version 10; SPSS Inc;
Chicago, IL) and StatsDirect (StatsDirect, version 2.7.2 for
MS-Windows, England, StatsDirect Ltd, 2005. http://www.
statsdirect.com). Data are presented in a descriptive
fashion as mean (95% confidence intervals [CI]) or
percentage (95% CI). Categorical variables were compared
using the chi-square test while Mann-Whitney U test was
used as applicable in case of continuous variables. To
analyze the factors predicting poor outcome (i.e. relapses
and failure to achieve complete remission), a multivariate
logistic regression analysis was performed to derive
adjusted odds ratio (AOR) and 95% confidence intervals (CI)using the following variables: duration of asthma, lung
function abnormality on spirometry, absolute eosinophil
count, IgE levels (both total and Af specific), percentage
decline in IgE levels after six weeks of glucocorticoids,
extent of bronchiectasis based on the number of segments
involved on HRCT and the presence of hyperattenuating
mucus. Statistical significance was assumed at a p-value of
less than 0.05.
Results
During the study period, 242 patients with bronchial asthma
were screened for ABPA using aspergillus skin test; 87
(35.9%) patients were found to be positive and 54 (22.3%)
patients were diagnosed to have ABPA. There were 29
males and 25 females with a mean age of 34.3 (95% CI,
30.6e38.0) years. The baseline characteristics of these
patients with regards to clinical features, spirometry,
serological findings and HRCT manifestations are shown in
Table 1. The recognition of ABPA was generally delayed,
and around 33 percent of patients had received antituber-
cular therapy in the past, median 1 (range, 1e2). Chest
Table 3 Outcome of allergic bronchopulmonary
aspergillosis.
Total (nZ 54)
Duration of glucocorticoid
therapy (months)
10.5 (9.2e11.9)
Remission 54 (100; 93.4e100)
Relapse 24 (44.4; 32.0e57.6)
Complete remission 39 (72.2; 59.1e82.4)
Glucocorticoid-dependent ABPA 15 (27.8; 17.6e40.9)
Follow-up (months) 20.1 (16.9e23.2)
All the results are expressed as mean (95% confidence intervals)
and number (percentage) unless otherwise stated.
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(35.2%) patients. Ten (18.5%) patients had a normal HRCT
(serologic ABPA [ABPA-S]) and 44 (81.5%) had bronchiectasis
(ABPA-central bronchiectasis [ABPA-CB]). The mean (range)
number of lobes and segments involved were 3 (0e5) and
6 (0e18) respectively. Twelve (22.2%) patients were iden-
tified to have high-attenuation mucus impaction on HRCT at
presentation.
There was clinical and radiological improvement in all
the patients receiving glucocorticoid therapy at six weeks.
The mean IgE levels at baseline were 7829 IU/mL, and fell
by a mean of 38.8 (95% CI, 32.4e45.1) percent (Table 2).
The percentage decline in IgE levels was significantly higher
in patients with IgE levels more than 2500 IU/mL (Table 2).
Twenty-two (40.7%) patients did not attain a 35 percent
decline in IgE levels at six weeks although 100 percent
could achieve this decline at three months. Also a higher
proportion of patients with IgE levels of more than 2500 IU/
mL were able to attain a 35% decline in IgE levels at six
weeks (Table 2), and this difference was statistically
significant (pZ 0.004). There was no difference in the
absolute or percentage decline of IgE levels in patients with
central bronchiectasis (ABPA-CB) or those without.
The mean duration of follow-up was 20.1 months
(95% CI, 16.9e23.2). All the patients went into remission at
three months (Table 3). Twenty four (44%) patients had
a relapse during the course of their treatment. All these
patients were restarted on therapy with prednisolone and
itraconazole. Of the 24 patients who relapsed, all could
achieve remission; however therapy could be stopped only
in 8 patients (i.e. complete remission). Thirty nine patients
were classified to have undergone complete remission. The
dosage of steroids was tapered, and therapy was stopped at
a mean duration of 10.5 months (95% CI, 9.2e11.9 months)
in these patients. Fifteen (27.8%) patients were maintained
on long-term treatment with steroids and were classified as
having glucocorticoid-dependent ABPA.
Multivariate logistic regression analysis was performed
to identify the factors predicting relapse and failure to
achieve complete remission. After adjustment for duration
of asthma, abnormal lung function, absolute eosinophil
count, IgE levels [total and Af specific], the severity ofTable 2 Decline in IgE levels at six weeks.
Percentage decline
Baseline IgE 2500 IU/mL (nZ 11)
Baseline IgE >2500 IU/mL (nZ 43)
All patients (nZ 54)
35% decline in IgE levels
IgE 2500 IU/mL (
IgE decline< 35% 9 (81.8; 52.3e94.5
IgE decline 35% 2 (18.2; 51.4e47.7
Decline in ABPA-s vs. ABPA-CB
ABPA-s (nZ 10)
Absolute decline 2652 (399e4905)
Percentage decline 35.8 (26.6e45.1)
All the results are expressed as mean (95% confidence intervals) and nu
stated.
*p-value less than 0.05.bronchiectasis (based on the number of segments involved)
and the presence of high-attenuation mucus, the
percentage decline in IgE levels at six weeks did not predict
occurrence of relapse and failure to achieve complete
remission (Table 4). The severity of bronchiectasis and
presence of high-attenuation mucus predicted occurrence
of relapses whereas only the severity of bronchiectasis
predicted failure to achieve complete remission (Table 4).
Discussion
The results of this study suggest that not all patients ach-
ieve a 35 percent decline in total serum IgE levels beyond
six weeks even with institution of high dose glucocorticoid
therapy despite clinical and radiological improvement. The
quantum fall in total serum IgE levels is smaller in patients
with baseline IgE levels less than 2500 IU/mL, and this point
should be kept in mind while managing patients with ABPA.
The magnitude of decline in IgE levels did not predict the
occurrence of clinical outcomes in patient with ABPA. This
study also confirms our previous findings that only the
extent of bronchiectasis on HRCT predicted relapses and
the failure to undergo complete remission. The presence of
hyperdense mucus predicted only the occurrence of relapse
and a non-significant trend towards failure to achieve
complete remission in patients with ABPA.26.1% (19.9e32.3)
44% (38.9e49.1)*
38.8% (32.4e45.1)
nZ 11) IgE >2500 IU/mL (nZ 43)
) 13 (30.2; 18.6e45.1)
) 30 (69.8; 54.9e81.4)*
ABPA-CB (nZ 44)
4136 (2526e5745)
41.4 (36.1e46.7)
mber (percentage with 95% confidence intervals) unless otherwise
Table 4 Factors predicting relapse and complete remission in patients with allergic bronchopulmonary aspergillosis -
multivariate analysis. All the results are expressed as mean (95% confidence intervals) and number (percentage, 95% confidence
intervals) unless otherwise stated.
Variables Relapse (nZ 24) No relapse (nZ 30) Adjusted OR (95% CI)
Duration of asthma (in years) 10 (6.5e13.4) 12.2 (6.8e17.6) 1.06 (0.99e1.13)
Lung function abnormality on
spirometry
17 (70.8, 50.8e85.1) 23 (76.7, 59.1e88.2) 2.48 (0.37e16.83)
Absolute eosinophil count at
presentation, cells/mL
1095.9 (773.1e1418.7) 1185.6 (804.3e1567) 0.99 (0.99e1)
Total IgE levels at
presentation, IU/mL
8204.6 (5573.5e10835.7) 7529.3 (4808.6e10252) 1 (1e1)
Percentage decline in IgE levels
at six weeks
42.8 (35.8e49.8) 38.4 (32.1e44.7) 1.02 (0.95e1.1)
A. fumigatus specific IgE levels
at presentation, kUA/L
16.2 (8.7e23.7) 14.1 (5.6e22.5) 1.0 (0.96e1.04)
Lung segments involved by
bronchiectasis on HRCT
9.0 (7.1e10.8) 5.0 (3.2e6.9) 1.22 (1.03e1.45)*
Presence of high-attenuation
mucus
12 (50, 31.4e68.6) 2 (6.7, 1.8e21.3) 38.07 (1.96e740.24)*
Variables Complete remission (nZ 39) No complete remission (nZ 15) Adjusted OR (95% CI)
Duration of asthma (in years) 9.6 (6.9e12.4) 14.3 (5.9e22.8) 1.06 (0.99e1.13)
Lung function abnormality on
spirometry
29 (74.4, 58.9e85.4) 11 (73.3, 48.1e89.1) 1.64 (0.26e10.25)
Absolute eosinophil count at
presentation, cells/mL
1158.1 (853.4e1462.8) 1113.7 (640.9e1586.6) 1 (0.99e1.0)
Total IgE levels at
presentation, IU/mL
7242.3 (4990.3e9494.4) 9355.9 (5858.6e12853.2) 1 (1e1)
Percentage decline in IgE levels
at six weeks
38.6 (33.1e43.9) 45.1 (35.9e54.2) 1.07 (0.99e1.15)
A. fumigatus specific IgE levels
at presentation, kUA/L
16.2 (8.9e23.4) 12 (3.8e20.2) 0.96 (0.91e1.01)
Lung segments involved by
bronchiectasis on HRCT
5.8 (4.2e7.3) 9.4 (6.6e12.2) 1.29 (1.06e1.57)*
Presence of high-attenuation
mucus
6 (15.4, 7.2e29.7) 6 (40.0, 19.8-64.3) 2.79 (0.38-20.66)
*p< 0.05.
208 R. Agarwal et al.Very few studies have described the factors predicting
outcome in patients with ABPA complicating bronchial
asthma. In a study of 76 patients with ABPA, Greenberger
et al. suggested that ABPA-S is less severe immunologically,
however only the A. fumigatus specific IgG levels were
higher in patients with ABPA-CB compared to ABPA-S. Other
immunologic parameters were not significantly different
between the two groups.27 Kumar et al. had also classified
the disease into three groups e ABPA-S (mild), ABPA-CB
(moderate) and ABPA-CB-other radiologic findings (ORF).
However, this was a single study and included only 18
patients.28 In a large study of ABPA published from this
center (126 patients), we have shown that the clinical,
spirometric and immunologic findings were not significantly
different when classifying ABPA into two groups (ABPA-S
and ABPA-CB) or into the above mentioned three categories
(ABPA-S, ABPA-CB and ABPA-CB-ORF).17 In a recently pub-
lished multivariate analysis of 155 patients with ABPA, we
had demonstrated that the severity of bronchiectasis and
the presence of hyperattenuating mucoid impaction on
HRCT predicted relapses of ABPA and the severity of
bronchiectasis was an independent predictor of failure toachieve long-term remission.19 Thus, it remains prudent to
diagnose and treat ABPA early before bronchiectasis (which
is irreversible lung damage) sets in.
The IgE is the antibody associated with allergy and type I
hypersensitivity. Although IgE is the least abundant immu-
noglobulin isotype (normal serum IgG levels are almost 270
times that of serum IgE levels), it can trigger powerful
immunological responses, as in patients with ABPA. The
total serum IgE level is a sensitive marker of the immuno-
logical process in patients with ABPA, and is thus the most
useful test for diagnosis and follow-up of these patients.
The cutoff for total IgE serum level in patients with ABPA is
1000 IU/mL, and often may reach levels in tens of thou-
sands as noted in our study. In fact, a normal total serum
IgE level almost excludes active ABPA as the cause of
patient’s current symptoms (in a patient currently not on
glucocorticoid therapy). It is important to remember that
the level may not reach normal even after therapy with
glucocorticoids. Therefore, repeated measurements of IgE
levels need to be ascertained over time to determine the
baseline value for an individual patient during remission.
The serum IgE determination also represents an important
Significance of IgE decline in ABPA 209clinical tool with which to follow patients over time.
A doubling of the patient’s baseline IgE levels signifies
relapse of the disease. It was therefore logical to assume
that the magnitude of decline in serum IgE levels would
predict the clinical outcomes. But, the results of this study
that the quanta of decline in serum IgE levels are not
correlated with the clinical outcome. It is not only the
immunological activity, but also the treatment response to
glucocorticoid therapy in ABPA which is highly variable, and
the glucocorticoid therapy controls the immunologic
activity, albeit only temporarily.
The present study suggests that the presence of bronchi-
ectasis is a marker associated with frequent relapses and
failure to achieve complete remission. The presence of
bronchiectasis identifies a group of patient with prolonged
immunological responses against A. fumigatus antigens.
It may also be probable that it defines a subgroup of patients
with more severe inflammation. Recently, numerous genetic
abnormalities including interleukin-10 promoter and
surfactant protein polymorphisms have been identified in
patients with ABPA and certain genetic abnormalities may
predispose a patient to develop bronchiectasis.1 The occur-
rence of bronchiectasis also makes the patient more
susceptible to a persistent A. fumigatus colonization state
with resultant recurrent relapses. Thus, it is of paramount
importance to diagnose ABPA before bronchiectasis sets in
i.e. in the ABPA-S stage. The exact reason why hyper-
attenuating mucus is associated with poorer outcomes
remains unclear, possibly the higher attenuation points to
a more inspissated and impacted type of mucus. It may also
be hypothesized that patients with hyperattenuating mucus
have specific genetic alterations which lead to formation of
hyperdense mucus, and the genetic abnormalities dictate
a disease with more severe inflammation and poorer
outcomes. More research is needed to investigate the exact
reasons for this association.
What are the clinical implications of our study? The
results of this study suggest that a 35 percent decline in IgE
levels at six weeks is not an absolute criterion for remission
in patients with ABPA. The levels may vary from patient to
patient (32e45 percent) and the fall may be less brisk in
patients with total serum IgE levels less than 2500 IU/mL
(20e32 percent). Thus the results of follow-up IgE levels
need to be interpreted in the light of clinical findings.
If there is a clinical and radiological improvement and the
IgE levels fall by less than 35 percent at six weeks, one can
safely follow the patient with a repeat serum IgE levels at
three months. But, if the IgE levels decline by less than
35 percent and are associated with lack of clinical and
radiological response, then further scrutiny is required to
investigate the cause of a lack of decline. If no obvious
cause is found, the dose of glucocorticoids needs to be
increased to control the immunological activity, although
this study was not designed to make this assumption.Conclusions
In conclusion, the results of this study suggest that a 35%
decline in total serum IgE levels at six weeks is not seen in
all patients after institution of glucocorticoid therapy
despite clinical and radiological improvement. The fall inserum IgE levels is slower in patients with baseline IgE
levels less than 2500 IU/mL. These points should be kept in
mind while evaluating a patient with ABPA for remission.
Finally, the quantum of decline in serum IgE levels does not
predict clinical outcomes.
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